Why M&A strategy focusing on selling low-margin business inhibits innovation, lowers entry barriers, dilutes expertise, and weakens patient ties In the last...
It is time for cheaper, faster, more granular, and more precise clinical trials Discovering new drugs, repurposing or repositioning existing ones, and...
